The researchers began by asking a deceptively simple question: does the gut microbiome of β-thalassemia mice differ from that of healthy animals in ways that could influence disease severity? To find out, they collected fecal samples from wild-type and β-thalassemia mice and subjected them to 16S rRNA sequencing, a technique that reads the genetic barcodes of bacterial communities to map their composition. The analysis revealed that P. copri stood out as a dominant pro-inflammatory bacterium in the β-thalassemia animals, prompting the team to test whether the microbe was merely a bystander or an active contributor to the disorder’s hallmark iron overload and inflammation.

To answer that question, the investigators designed a four-group experiment that separated the effects of the mutation from the effects of the bacterium. They established wild-type mice, wild-type mice given P. copri, β-thalassemia mice, and β-thalassemia mice given P. copri, delivering the bacterium by intragastric gavage, a controlled oral transplantation technique that bypasses uncertainty about natural colonization. This design allowed the researchers to observe what happens when the microbe is introduced into a system already primed by the genetic disease, and to compare it against the same introduction in healthy animals.

The results were striking. Compared with untreated β-thalassemia mice, those that received P. copri showed elevated serum levels of the pro-inflammatory cytokines tumor necrosis factor-α, interleukin-1β, and interleukin-6, alongside a decrease in the anti-inflammatory cytokine interleukin-10. At the same time, serum ferritin, a clinical marker of the body’s iron stores, rose, while ferroportin, the membrane protein responsible for exporting iron from cells into the bloodstream, fell. All of these changes reached statistical significance at p < 0.05, indicating that the bacterium was not simply adding noise to the disease picture but actively pushing the animals toward greater iron retention.

The hematological consequences were equally telling. Hemoglobin levels dropped in the P. copri-treated β-thalassemia mice, while erythropoietin and reticulocyte counts climbed. This pattern suggests that the bacterium worsened the already inefficient erythropoiesis that defines β-thalassemia, forcing the body to compensate with higher erythropoietin output and increased production of immature red blood cells. The authors note that P. copri may further aggravate ineffective erythropoiesis and erythrocyte injury in these animals, compounding the central defect of the disorder rather than merely adding a secondary complication.

To understand the molecular mechanism behind these observations, the team turned to the JAK/STAT signaling pathway, a canonical route by which interleukin-6 and related cytokines transmit inflammatory signals from the cell surface to the nucleus. Using quantitative real-time reverse transcription polymerase chain reaction and Western blotting, they measured the expression of glycoprotein 130, the co-receptor that anchors interleukin-6 signaling, along with Janus kinase 1, signal transducer and activator of transcription 3, and the phosphorylated forms of both kinases. In the β-thalassemia mice given P. copri, the expression levels of GP130, the ratio of phosphorylated to total JAK1, and the ratio of phosphorylated to total STAT3 were all upregulated, indicating that the pathway had been switched into a higher gear by the bacterial intervention.

The tissue-level evidence reinforced the molecular findings. Hematoxylin-eosin staining of colonic tissue revealed mucosal damage accompanied by inflammatory cell infiltration in the P. copri-treated β-thalassemia mice, pointing to direct intestinal injury on top of the systemic inflammation. Prussian blue staining, which highlights iron deposits as blue granules under the microscope, showed markedly aggravated iron accumulation in both the liver and the spleen of the treated animals compared with untreated β-thalassemia controls. Together, these histological observations confirmed that the bacterium’s effects were not confined to blood markers but extended to visible organ pathology.

The authors propose that P. copri exacerbates iron overload by triggering inflammatory responses and upregulating hepcidin, the liver-derived hormone that acts as the master regulator of iron homeostasis. Hepcidin binds to ferroportin and causes it to be internalized and degraded, effectively locking iron inside macrophages, hepatocytes, and enterocytes. By elevating interleukin-6, a potent inducer of hepcidin expression, and subsequently activating the JAK/STAT signaling pathway, P. copri appears to set off a cascade that suppresses iron export and traps the metal in tissues, worsening the iron burden that already plagues β-thalassemia patients.

The study’s implications reach beyond the laboratory. β-thalassemia affects populations across the Mediterranean, the Middle East, and Southeast Asia, and iron overload remains a leading cause of morbidity in these patients despite chelation therapy. If gut microbes can modulate hepcidin and iron distribution through immune signaling, then microbiome-targeted interventions, whether through dietary modification, probiotics, or antibiotics, could theoretically complement existing treatments. The finding also adds to a growing body of evidence that the intestinal microbiota is not a passive passenger in hematological disease but an active participant capable of shaping inflammation, erythropoiesis, and metal metabolism.

As with any animal study, the results require careful interpretation before they can inform clinical practice. The mouse model does not fully recapitulate the human disease, and the specific contribution of P. copri in patients with β-thalassemia remains to be established through human cohort studies. Nevertheless, the mechanistic clarity of the work, linking a specific gut bacterium to a specific signaling pathway and a specific clinical problem, offers a concrete starting point for future investigations. The research was supported by the National Natural Science Foundation of China, the Guangxi Ba Gui Scholars Special Project, and the Guangxi Medical and Health Key Discipline Construction Project, and the full article is available open access in Annals of Hematology.

Subject of Research: The role of Prevotella copri in exacerbating iron overload and chronic inflammation in β-thalassemia mice through JAK/STAT pathway activation.

Article Title: Mechanistic insights into how Prevotella copri exacerbates tissue iron retention and chronic inflammation in β-thalassemia mice via activation of the JAK/STAT signaling pathway

Article References: Li, Y., Huang, T., Chen, G., Liu, Z., Li, J., Ke, Z., Li, Y., Song, J., Mo, L., & Zhu, C. (2026). Mechanistic insights into how Prevotella copri exacerbates tissue iron retention and chronic inflammation in β-thalassemia mice via activation of the JAK/STAT signaling pathway. Annals of Hematology. https://doi.org/10.1007/s00277-026-07320-6

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07320-6

Keywords: Prevotella copri, β-thalassemia, iron overload, JAK/STAT signaling pathway, chronic inflammation, gut microbiome, hepcidin, interleukin-6, ferroportin, ineffective erythropoiesis, Annals of Hematology, Mechanistic

At the cellular level, the master regulators are the iron regulatory proteins, IRP1 and IRP2, which operate through a remarkably elegant post-transcriptional circuit. These proteins bind to iron-responsive elements, or IREs, which are hairpin structures folded into the untranslated regions of specific messenger RNAs. When cellular iron is scarce, IRPs clamp onto IREs located near the start of transcripts, physically blocking the ribosome from translating them. This is how the cell silences production of ferritin, the iron-storage protein, and of ferroportin, the sole known iron exporter, ensuring that whatever iron is present stays inside the cell rather than being locked away or shipped out. Simultaneously, the same IRPs bind IREs in the 3-prime untranslated region of the transcript encoding transferrin receptor 1, the protein that imports iron-bound transferrin from the blood. There, binding stabilizes the mRNA against degradation, boosting receptor production and iron uptake. The result is a two-pronged switch: low iron turns on import and turns off export and storage, while iron abundance flips the entire program in the opposite direction.

The sensing mechanism itself is a story of molecular transformation. IRP1 is, in fact, a dual-function protein: when iron is plentiful, it assembles a 4Fe-4S iron-sulfur cluster into its active site and converts into cytosolic aconitase, an enzymatic relic of its evolutionary origin, losing its RNA-binding capacity in the process. When iron levels fall, the cluster disassembles and the protein reverts to its RNA-binding form. IRP2, which lacks the aconitase function, is regulated instead through iron-dependent degradation: in iron-replete conditions it is ubiquitinated following iron-dependent oxidation and destroyed by the proteasome. Two sensors, two mechanisms, one coherent output. This system also intersects with oxygen sensing, because hypoxia modulates IRP activity, linking iron availability to the oxygen-dependent metabolic state of the cell, a connection reflected in the review’s emphasis on hypoxia as a keyword of the field.

Cellular control, however, is only half the story. The body must decide globally how much iron to absorb from the diet, how much to release from storage, and how much to allocate to the single largest iron consumer: the erythron, the billions of developing red blood cells that require roughly twenty to twenty-five milligrams of iron daily in an adult human. Humans have no regulated route of iron excretion, so systemic balance is achieved almost entirely by controlling absorption at the duodenal enterocyte and release from iron-recycling macrophages. The linchpin of this control is hepcidin, a 25-amino-acid peptide hormone produced by the liver. Hepcidin binds to ferroportin on the surface of enterocytes, macrophages, and hepatocytes, triggering its internalization and degradation. With ferroportin removed, iron can neither leave the gut into the blood nor exit storage sites, and plasma iron falls. In effect, hepcidin is the body’s iron gatekeeper, and its concentration in plasma determines the flow of iron through the entire economy of the organism.

What makes hepcidin fascinating to researchers is the sophistication of its upstream wiring. The central signaling axis runs through the bone morphogenetic protein pathway: BMP6, produced in response to iron loading of liver sinusoidal endothelial cells, signals through SMAD transcription factors to switch on the HAMP gene encoding hepcidin. This pathway is tuned by a cast of accessory proteins. Hemojuvelin, encoded by HJV, acts as a co-receptor that amplifies BMP-SMAD signaling; mutations in HJV cause the most severe form of hereditary hemochromatosis, juvenile type, precisely because hepcidin production collapses. The transmembrane protease TMPRSS6, also known as matriptase-2, cleaves hemojuvelin from the cell surface, dampening the signal; loss-of-function mutations in TMPRSS6 produce iron-refractory iron deficiency anemia, a condition in which hepcidin remains inappropriately high and dietary iron cannot be absorbed. The review highlights FKBP12 as another layer of this circuit, a cytosolic protein that restrains BMP receptor signaling and thereby modulates hepcidin output, illustrating how finely the pathway is calibrated.

On top of the iron-sensing machinery sits a second regulatory layer that reads the body’s demand for iron. Transferrin receptor 2, a hepatocyte protein homologous to TFR1 but unable to bind IREs, senses the degree of transferrin saturation in plasma and transmits that information into the hepcidin pathway, working with the hemochromatosis protein HFE. Meanwhile, when red blood cell production accelerates, for example after hemorrhage, at altitude, or in response to anemia, erythroid cells in the bone marrow secrete erythroferrone, a hormone that suppresses hepcidin production, opening the ferroportin gates so that iron reserves can flow to the marrow. Inflammation adds yet another input: the cytokine interleukin-6 drives hepcidin up through the JAK-STAT pathway, sequestering iron in macrophages and hepatocytes and contributing to the anemia of chronic disease. The review’s central argument is that hepcidin regulation is not a single linear pathway but a dynamic integration hub, layering metabolic, stress, and environmental cues onto the core iron signal.

When these circuits fail, the clinical consequences are the disorders that have shaped human medicine for centuries. In hereditary hemochromatosis, mutations in HFE, TFR2, HJV, or hepcidin itself leave hepcidin inappropriately low relative to iron stores. Ferroportin stays active, dietary iron is absorbed relentlessly, and over decades the metal accumulates in the liver, pancreas, heart, and joints, causing cirrhosis, diabetes, cardiomyopathy, and arthritis if untreated. The disease illustrates the asymmetry of the system: because there is no excretory route, a small deficit in hepcidin translates into a lifelong positive iron balance. Conversely, when hepcidin is chronically elevated, as in inflammatory states or TMPRSS6 mutations, iron is locked away from the plasma and patients develop anemia that does not respond to oral iron supplementation, because the absorptive gate itself is closed.

Iron deficiency, the most common nutritional disorder worldwide, and iron overload thus represent opposite failures of the same regulatory logic, and understanding the circuits opens therapeutic doors. Drugs that stimulate the BMP-SMAD pathway or inhibit TMPRSS6 could raise hepcidin in beta-thalassemia and other iron-loading anemias, where suppressed hepcidin causes secondary overload even without transfusions. Conversely, hepcidin antagonists, including anti-hepcidin antibodies and BMP pathway inhibitors, could lower the hormone in anemia of inflammation, releasing iron trapped in macrophages. The review also points to emerging functions of iron-regulatory proteins that extend beyond their established roles, suggesting that IRPs and hepcidin pathway components participate in processes such as epigenetic regulation and stress responses, hinting that the iron system’s influence on physiology may be broader than the classical picture suggests.

What emerges from the synthesis is a picture of biological control at its most refined: a two-tier architecture in which every cell runs its own iron budget through post-transcriptional sensing, while a central hormonal circuit integrates stores, circulating iron, erythropoietic demand, inflammation, and hypoxia into a single systemic signal. The two tiers talk to each other, since ferroportin is both the target of hepcidin and an IRP-regulated transcript, creating feedback loops that span from the ribosome to the whole organism. For a field that began with the discovery of ferritin more than ninety years ago, the pace of discovery remains striking, and the Italian team’s comprehensive map arrives at a moment when hepcidin-targeted therapies are entering clinical development. Iron built the modern world of steel and oxygen, and inside our bodies, an equally engineered system of sensors, gates, and hormones keeps it in perfect, life-sustaining check.

Subject of Research: Molecular mechanisms of cellular and systemic iron homeostasis

Article Title: Circuits that guarantee iron homeostasis: from cellular sensing to systemic control

Article References: Silvestri, L., Pettinato, M., Carleo, R., Furiosi, V., Nai, A., & Pagani, A. (2026). Circuits that guarantee iron homeostasis: from cellular sensing to systemic control. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06422-8

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06422-8

Keywords: iron homeostasis, hepcidin, ferroportin, IRE-IRP system, transferrin receptor, BMP-SMAD pathway, TMPRSS6, hemochromatosis, iron deficiency, erythroferrone, hypoxia, gene regulation